Timur KÖSE, Sinem ERMİN, Gürsel ÇOK, Ali VERAL

The role of apelin in the assessment of response to chemotherapyand prognosis in stage 4 nonsmall cell lung cancer

Background/aim: Prediction of response to chemotherapy and prognosis bears clinical significance in patients with lung cancer. The aim of the study was to examine the association between apelin expression in tumor tissues and overall survival, progression-free survival, chemoresistance, and treatment response in stage 4 nonsmall cell lung cancer (NSCLC) patients undergoing chemotherapy. Materials and methods: A total of 81 patients who received chemotherapy due to a biopsy-documented diagnosis of NSCLC between 2004 and 2011 were retrospectively studied. Bronchoscopic biopsy samples were examined immunohistochemically. Results: Of the overall study population (n = 81), the mean age was 59.0 ± 9.2 years; 83% (n = 67) were male and 17% (n = 14) were female. All patients received chemotherapy. A total of 30 patients (37%) had no apelin positivity, while 21 (30%) had 1 +, 20 (25%) had 2 +, and 10 (12%) had 3 + apelin positivity. We detected no association between apelin positivity and overall survival, 6-month survival, or 1-year survival rates (P = 0.05, 0.74, and 0.63). Patients with apelin expression as compared to those without it had shorter overall survival (P = 0.05). Conclusion: Our results suggest that apelin, an angiogenic factor, does not seem to provide significant prognostic information in this patient group.

PDF

___

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics; 2002. CA-Cancer J Clin 2005; 55: 74-108.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics; 2005. CA-Cancer J Clin 2005; 55: 10-30.
3. Aydıner A, Topuz E. Akciğer Kanseri İstanbul Konsensusu. Ankara, Turkey: Nobel Tıp Basımevi; 2006 (in Turkish).
4. Albert AJ, Samet JM. Epidemiology of lung cancer. Chest 2007; 132: 29-55.
5. Aydıner A, Ece T, Topuz E. Akciğer Kanseri Antakya Konsensusu. Ankara, Turkey: Nobel Tıp Basımevi; 2010 (in Turkish).
6. Wald NJ, Nanchahal K, Thompson SG, Cuckle HS. Does breathing other peoples smoke cause lung cancer? BMJ 1986; 293: 1217-1222.
7. Omenn GS, Merchant J, Boatmann E, Dement JM, Kuschner M, Nicholson W, Peto J, Rosenstock L. Contribution of environmental fibers to respiratory cancer. Environ Health Persp 1986; 70: 51-56.
8. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics; 2008. CA-Cancer J Clin 2008; 58: 71-96.
9. Giuseppe G. The potential of antiangiogenic therapy in nonsmall cell lung cancer. Clin Cancer Res 2007; 13: 1961-1970.
10. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991.
11. Tsao MS, Aviel-Ronen S, Ding K, Lau D, Liu N, Sakurada A, Whitehead M, Zhu CQ, Livingston R, Johnson DH et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol 2007; 25: 5240-5247.
12. ODowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, George SR, Nguyen T. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993; 136: 355-360.
13. Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, Fujimiya M. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Peptides 2001; 99: 87-92.
14. Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A, Castan-Laurell I, Tack I, Knibiehler B, Carpene C et al. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146: 1764-1771.
15. Falcao-Pires I, Castro-Chaves P, Miranda-Silva D, Lourenço AP, Leite-Moreira AF. Physiological, pathological and potential therapeutic roles of adipokines. Drug Discov Today 2012; 17: 880-889.
16. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, Kitada J, Honda S, Kurokawa T, Onda H et al. Molecular and functional characteristics of APJ. Tissue distribution of MRNA and interaction with the endogenous ligand apelin. J Biol Chem 2000; 275: 21061-21067.
17. Kidoya H, Ueno M, Yamada Y, Mochizuki N, Nakata M, Yano T, Fujii R, Takakura N. Spatial and temporal role of the apelin/ APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 2008; 27: 522-534.
18. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005; 198-211.
19. Berta J, Kenessey I, Dobos J, Tovari J, Klepetko W, Ankersmit HJ, Hegedus B, Renyi-Vamos F, Varga J, Lorincz Z et al. Apelin expression in human non-small cell lung cancer, role in angiogenesis and prognosis. J Thorac Oncol 2010; 5: 1120- 1129.
20. Heo K, Kim YH, Sung HJ, Li HY, Yoo CW, Kim JY, Park JY, Lee UL, Nam BH, Kim EO et al. Hypoxia-induced up-regulation of apelin is associated with a poor prognosis in oral squamous cell carcinoma patients. Oral Oncol 2012; 48: 500-506.
21. Wang Z, Greeley GH Jr, Qiu S. Immunohistochemical localization of apelin in human normal breast and breast carcinoma. J Mol Histol 2008; 39: 121-124.